Last reviewed · How we verify
metformin+empagliflozin+insulin glargine
metformin+empagliflozin+insulin glargine is a SGLT2 inhibitor, insulin analog, biguanide Small molecule drug developed by Xiangya Hospital of Central South University. It is currently in Phase 3 development for Type 2 diabetes, Chronic kidney disease.
Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while empagliflozin inhibits SGLT2 to reduce glucose reabsorption in the kidneys, and insulin glargine is a long-acting insulin analog that helps lower blood sugar levels.
Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while empagliflozin inhibits SGLT2 to reduce glucose reabsorption in the kidneys, and insulin glargine is a long-acting insulin analog that helps lower blood sugar levels. Used for Type 2 diabetes, Chronic kidney disease.
At a glance
| Generic name | metformin+empagliflozin+insulin glargine |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Drug class | SGLT2 inhibitor, insulin analog, biguanide |
| Target | SGLT2, insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Metformin's action on the liver and insulin sensitivity helps to lower blood glucose levels. Empagliflozin's inhibition of SGLT2 reduces glucose reabsorption in the kidneys, also lowering blood glucose levels. Insulin glargine, a long-acting insulin analog, helps to regulate blood sugar levels by providing a steady supply of insulin.
Approved indications
- Type 2 diabetes
- Chronic kidney disease
Common side effects
- Nausea
- Diarrhea
- Hypoglycemia
- Ketoacidosis
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Changing the Natural History of Type 2 Diabetes ("CHANGE" Study) (NA)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy (PHASE3)
- Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? (NA)
- Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin+empagliflozin+insulin glargine CI brief — competitive landscape report
- metformin+empagliflozin+insulin glargine updates RSS · CI watch RSS
- Xiangya Hospital of Central South University portfolio CI
Frequently asked questions about metformin+empagliflozin+insulin glargine
What is metformin+empagliflozin+insulin glargine?
How does metformin+empagliflozin+insulin glargine work?
What is metformin+empagliflozin+insulin glargine used for?
Who makes metformin+empagliflozin+insulin glargine?
What drug class is metformin+empagliflozin+insulin glargine in?
What development phase is metformin+empagliflozin+insulin glargine in?
What are the side effects of metformin+empagliflozin+insulin glargine?
What does metformin+empagliflozin+insulin glargine target?
Related
- Drug class: All SGLT2 inhibitor, insulin analog, biguanide drugs
- Target: All drugs targeting SGLT2, insulin receptor
- Manufacturer: Xiangya Hospital of Central South University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Chronic kidney disease
- Compare: metformin+empagliflozin+insulin glargine vs similar drugs
- Pricing: metformin+empagliflozin+insulin glargine cost, discount & access